FiercePharma1d
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
manilatimes1d
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...
manilatimes1d
AGF Management Limited Declares Fourth Quarter 2024 Dividend
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- On December 13, 2024, the Board of Directors of AGF Management Limited declared a ...
Business Insider1d
BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment
Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive ...
TCTMD1d
Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality
The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.